Bercoff E, Bataille C, Pariente A E, Valla D, Delhotal B, Lebrec D
Hepatology. 1984 May-Jun;4(3):451-3. doi: 10.1002/hep.1840040317.
Fourteen patients with cirrhosis and bleeding esophageal varices were treated with propranolol. The dose of propranolol was determined by decreasing the resting heart rate by 25% 12 hr after an oral dose of propranolol which was given twice a day. Significant decreases in the hepatic venous pressure gradient and cardiac output after 1 month of propranolol administration was observed. To assess beta-adrenergic blockade, the isoproterenol test and plasma propranolol levels were evaluated. Increasing doses of isoproterenol were injected to increase the resting heart rate 25 beats per minute (chronotropic dose 25 or CD25 ). Plasma propranolol concentrations were measured in blood samples drawn 4 hr after the last oral dose. The mean CD25 was 5 +/- 2 micrograms before and 146 +/- 84 micrograms after 1 month of propranolol administration. The plasma propranolol level after 1 month of drug administration was 0.69 +/- 0.47 microM per liter i.e. 2.33 +/- 1.59 micrograms per ml. A significant correlation was found between the CD25 measured after continuous propranolol administration and plasma propranolol level. In conclusion, the efficacy of beta-adrenergic blockade was estimated by the isoproterenol test which correlates with the plasma propranolol level in patients with cirrhosis. This study suggests that the isoproterenol test is useful in assessing beta-adrenergic blockade with propranolol in patients with cirrhosis.
14例肝硬化合并食管静脉曲张出血患者接受了普萘洛尔治疗。普萘洛尔剂量通过口服给药(每日2次)12小时后使静息心率降低25%来确定。观察到普萘洛尔给药1个月后肝静脉压力梯度和心输出量显著降低。为评估β-肾上腺素能阻滞,进行了异丙肾上腺素试验并检测血浆普萘洛尔水平。注射递增剂量的异丙肾上腺素以使静息心率每分钟增加25次(变时剂量25或CD25)。在最后一次口服给药4小时后采集血样测定血浆普萘洛尔浓度。普萘洛尔给药1个月前平均CD25为5±2微克,给药1个月后为146±84微克。给药1个月后血浆普萘洛尔水平为每升0.69±0.47微摩尔,即每毫升2.33±1.59微克。持续服用普萘洛尔后测得的CD25与血浆普萘洛尔水平之间存在显著相关性。总之,通过异丙肾上腺素试验评估β-肾上腺素能阻滞的疗效,该试验与肝硬化患者血浆普萘洛尔水平相关。本研究表明,异丙肾上腺素试验有助于评估肝硬化患者使用普萘洛尔时的β-肾上腺素能阻滞情况。